TG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

TG Therapeutics (NASDAQ:TGTX) issued its earnings results on Monday. The biopharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.02), FiscalAI reports. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The firm had revenue of $259.94 million during the quarter, compared to analysts’ expectations of $245.47 million.

TG Therapeutics Price Performance

TGTX opened at $59.83 on Monday. The business has a 50 day moving average of $55.80 and a 200-day moving average of $44.50. The stock has a market capitalization of $9.16 billion, a price-to-earnings ratio of 21.84, a P/E/G ratio of 2.53 and a beta of 1.89. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics has a 1-year low of $26.76 and a 1-year high of $63.60.

Insider Transactions at TG Therapeutics

In related news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 8.87% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. B. Riley Financial raised their price objective on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $63.00.

TG Therapeutics Company Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.